Regent Pacific Launches Accrua: A New Era in Digital Health and Telehealth

In an exciting move, Regent Pacific Group Limited, a diversified investment entity based in Hong Kong, is launching Accrua, a cutting-edge consumer digital health and telehealth platform. This initiative, spearheaded by Deep Longevity, Regent Pacific's subsidiary focusing on AI-driven biological aging intelligence, is set to enter the United States market in October 2026. This announcement marks a significant turn towards personalized healthcare that emphasizes biological metrics over traditional symptom-based assessments.

A Revolutionary Approach to Health

Accrua aims to provide accessible health solutions tailored to individual biological ages, rather than just symptom reports. This innovative platform will be available to consumers in all 50 US states from the moment of launch, offering clinician-guided health care that is both personalized and science-based. The integration of Deep Longevity's proprietary technology, including the acclaimed BloodAge report, will allow individuals to understand their aging process more comprehensively. This report utilizes routine blood tests to establish if a person is aging faster biologically compared to their chronological age.

Following an initial consultation with licensed US clinicians, users of Accrua will have access to a broad spectrum of specialized treatment options. These will include medications such as glucagon-like peptide-1 (GLP-1) therapies for weight management, as well as treatments for both men’s and women’s health issues, including hormone replacement therapies. Each treatment plan is uniquely crafted by clinicians based on individual BloodAge assessments, making it a more accurate reflection of personal health needs than traditional methods that rely on self-reported symptoms.

Backed by Research

At the core of the Accrua platform is a commitment to scientific accuracy and validated research. The BloodAge model has been thoroughly examined in peer-reviewed studies, demonstrating that deviations between biological and chronological age can be significant. Notably, a recent study published in Aging and Disease found that a one-year gap between these ages can increase mortality risk by 15%. Furthermore, Deep Longevity's innovative approach was recognized as a runner-up in a prestigious global competition, competing against 150 other companies.

Market Potential and Business Model

The timing of Accrua's launch aligns perfectly with the growing demand for digital health platforms in the US. The market already shows significant potential, with recent platforms directed at similar health categories generating impressive revenues. For instance, MEDVi, LLC raked in over USD 400 million in its inaugural year, illustrating consumers' willingness to invest in digital health solutions.

Regent Pacific plans to leverage a capital-efficient and scalable business model for Accrua. By utilizing established telehealth partner networks and a robust team of independent, licensed physicians and pharmacies, the platform aims to minimize its upfront investment needs while simultaneously maximizing operational flexibility. The anticipated revenue will primarily stem from subscription-based offerings, set within a HIPAA-compliant operational structure and aiming for LegitScript certification.

Looking Ahead

Jamie Gibson, CEO of Regent Pacific, notes the pivotal nature of Accrua's introduction, emphasizing its potential to change the healthcare landscape fundamentally. By anchoring treatment to biological measures instead of just symptomatic analysis, Accrua presents a novel proposition in an already dynamic market. As the anticipation builds for this groundbreaking launch, stakeholders are encouraged to watch how this venture may reshape health care access across the US.

In conclusion, Accrua represents not just a new product launch, but a forward-thinking movement towards personalized healthcare. By integrating advanced technology with clinical expertise, Regent Pacific and Deep Longevity are set to lead consumers into a new chapter of health management that focuses on the essence of aging — our biological realities.